Ultragenyx Takes On Rare Childhood Disease With In-licensing Deal
This article was originally published in The Pink Sheet Daily
Rare disease company Ultragenyx has in-licensed the North American rights to a treatment for fatty-acid oxidation disorder, adding its third clinical-stage drug to its ultra-rare disease pipeline.
You may also be interested in...
The rare disease biotech is confident it can move all of its programs forward and has no interest in selling its commercialization rights to a Big Pharma partner.
GSK’s venture arm outlines its investment priorities, which involve changes to the biopharma business model.
Ultragenyx raised $75 million in a Series B financing led by Adage Capital Partners. The funding will support the biotech’s two lead programs that are meant to treat ultra-rare genetic disorders and will position the company for an initial public offering.